New York Times’ stock falls as analysts question its promotional spending

• Uber’s stock falls in the face of its ‘strongest quarter ever.’ Here’s why.

  The ride-hailing company faces stiff pressure from the strong U.S. dollar, which is weighing on its forecast for the current quarter.
  
  MarketWatch - 4h

• Pfizer’s stock falls despite fourth-quarter revenue and earnings beat. This analyst expects growth to accelerate.

  Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its fourth-quarter results.
  
  MarketWatch - 22h

• Nvidia’s stock falls as these two questions dog investors

  Wall Street is trying to assess how tariffs would impact the chip sector. Plus, the DeepSeek fallout lingers.
  
  MarketWatch - 1d

• GM stock falls even as company beats analyst expectations on earnings

  While investors will be watching GM's quarterly results, they will also be focused on its guidance for 2025 and any changes under the Trump administration.
  
  CNBC - Jan. 28

• GM’s stock falls as carmaker signals that tariffs may impact its outlook

  GM topped Wall Street’s fourth-quarter adjusted profit estimate as sales rose 11%, but the carmaker’s stock fell back.
  
  MarketWatch - Jan. 28

• How the New York Times Website Got Its URL

  The Times wanted to go online in 1996 with nytimes.com. But the domain was already owned — by a Times reporter.
  
  The New York Times - Jan. 25
• 

  New York Yankees Done With Big Spending in Busy Offseason

  The New York Yankees are done signing high-priced free agents, a source with knowledge of their situation said. That leaves coveted players such as Pete Alonso and Alex Bregman among the 164 free ...
  
  Yahoo Sports - Jan. 9

• Nvidia’s stock falls further — but analysts see a future that’s brighter than ever

  Nvidia’s talk of huge market opportunities in autonomous driving and robotics is “potentially comforting for investors thinking about what might come next for the company,” an analyst says.
  
  MarketWatch - Jan. 8

More from MarketWatch

• My friend, 62, was given 6 months to live, but he may only have weeks. How does he prevent his second wife from inheriting everything?

  “Without his disability checks, his second wife might end up having to sell the house.”
  
  MarketWatch - 48m

• ‘Our tech stocks have done well’: We’re in our mid-50s and 85% invested in stocks. Is this too aggressive for the next 10 years?

  “Between our rentals, our stock portfolio, and our 401(k)s and IRAs we’ll have about $3 million with a paid-off home.”
  
  MarketWatch - 53m

• This is how much Mattel’s $600 million buyback could boost earnings

  Mattel is ramping up its share repurchase efforts. Analyst firm UBS expects an earnings boost from the toy maker.
  
  MarketWatch - 55m

• Oil prices drop on rising U.S. inventories and fears tariffs will dent Chinese demand

  Oil futures fell Wednesday, poised to mark their lowest settlement of the year so far, after official U.S. data showed a weekly climb of nearly 9 million barrels in U.S. crude inventories and as ...
  
  MarketWatch - 56m

• Why Trump’s sovereign-wealth fund won’t MAGA

  I’ll take a hard pass on this idea
  
  MarketWatch - 58m

More in Business

• Could Trump's tariffs replace the income tax? Here's what policy experts say

  During the campaign, President Donald Trump floated an "all tariff policy" to replace the federal income tax. Here's what experts say about the idea.
  
  CNBC - 12m

• What the 'mother of all trade wars' can teach us about U.S. tariffs, according to economists

  Here's how current events are mirroring a key point in U.S. history that led to a trade war and exacerbated the Great Depression, according to economists.
  
  CNBC - 20m

• National Women's Soccer League agrees to $5 million settlement over past mistreatment of players

  The NWSL and three attorneys general have agreed to a settlement over the league's past mistreatment of players.
  
  CNBC - 22m
• 

  Novo Nordisk Annual Sales Jump on Demand for Ozempic and Wegovy

  The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.
  
  The New York Times - 29m
• 

  Wall Street quizzes US companies over tariff risks

  Analysts bombard executives of listed companies with questions on coping with trade wars
  
  Financial Times - 30m